Key result
Aspirin 500 mg, contrary to other antiplatelet drugs, significantly depressed thrombin formation in clotting blood both in vitro and ex vivo.
Why the study?
Do antiplatelet drugs reduce thrombin generation in healthy volunteers?
Population
Healthy volunteers
Comparison
Aspirin 500 mg, indomethacin 50 mg, OKY-046 400… vs Placebo
Design
Other
Follow-up
Up to 5 days
Authors
Loading...
Aspirin impairs thrombin formation ex vivo in volunteers; leaves open contribution to clinical antithrombotic effects.
Do antiplatelet drugs reduce thrombin generation in healthy volunteers?
Aspirin, unlike other antiplatelet drugs tested, depresses thrombin formation in clotting blood, suggesting an additional mechanism of action beyond platelet inhibition.
Szczeklik et al. (1992) studied Healthy volunteers. Antiplatelet drugs (aspirin, indomethacin, OKY-046, ticlopidine) vs. Placebo was evaluated on Thrombin formation (in vitro and ex vivo). Aspirin 500 mg, contrary to other antiplatelet drugs, significantly depressed thrombin formation in clotting blood both in vitro and ex vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: